Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 844 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Attention Deficit and Disruptive Behavior Disorders Clear all
Completed Phase 2 Interventional

Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder

NCT00947973
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Challenging Horizons Program (CHP) after-school model, Challenging Horizons Program (CHP) consultation model
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 15 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Athens, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Assessing and Addressing Behaviors in Children With Hearing Loss

NCT02423746
View directory record Official record
Conditions
Hearing Loss, Attention Deficit and Disruptive Behavior Disorders, Parenting
Interventions
Family Check Up Behavioral Parenting Training Program (BPT), Behavioral Placebo
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Lexington, Kentucky • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children

NCT01554527
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Child Behavior Disorders, Attention Deficit Disorder With Hyperactivity, Disorders of Excessive Somnolence
Interventions
CPAP treatment, No CPAP treatment
Procedure · Other
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Home Based Treatment for Drug Use in Early Adolescents

NCT00280228
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder, Substance Abuse
Interventions
Adolescent Skills Parent Management Parent-Adol Negotiation, Treatment as Usual
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
11 Years to 14 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 6, 2026, 9:33 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder

NCT00863499
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Short Acting Methylphenidate, Long Acting Methylphenidate
Drug
Lead sponsor
BRC Operations Pty. Ltd.
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,344 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
5
States / cities
Colton, California • Tarzana, California • Englewood Cliffs, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 6, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Target ADHD Executive Working Memory Replication Study

NCT06446284
View directory record Official record
Conditions
ADHD
Interventions
EWM Training, Placebo Training
Behavioral
Lead sponsor
Hartford Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 6, 2026, 9:33 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

HOPS Study: A Conceptual Replication

NCT04465708
View directory record Official record
Conditions
Executive Dysfunction, Attention Deficit Hyperactivity Disorder
Interventions
Homework, Organization, and Planning Skills
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
11 Years to 15 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

NCT00029614
View directory record Official record
Conditions
Substance Use Disorders, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
13 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2010 · Synced Oct 6, 2026, 9:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Children at Risk for Disruptive Behavior Disorders

NCT00001233
View directory record Official record
Conditions
Attention Deficit and Disruptive Behavior Disorders, Child Behavior Disorders, Passive-Aggressive Personality Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD

NCT02251743
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Neurofeedback treatment
Device
Lead sponsor
Ohio State University
Other
Eligibility
7 Years to 10 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Asheville, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Trigeminal Nerve Stimulation for ADHD

NCT02155608
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
Active eTNS, Sham eTNS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
8 Years to 12 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Results available

Sequencing Treatments for Mothers With ADHD and Their At - Risk Children

NCT01816074
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Vyvanse (lisdexamphetamine), Behavior Parent Training
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Results available

Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD

NCT00585910
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine and OROS Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

NCT01907360
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder
Interventions
HLD200 (methylphenidate hydrochloride)
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 6, 2026, 9:33 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

NCT04987762
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Adhansia XR
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
4 Years to 12 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 6, 2026, 9:33 AM EDT
Not listed Not applicable Interventional

Reading Remediation and Outcomes in Detention

NCT03261076
View directory record Official record
Conditions
Specific Learning Disorder (MeSH Unique ID: D000067559), Dyslexia (MeSH Unique ID: D004410), Conduct Disorder (MeSH Unique ID: D019955)
Interventions
Strategies Enhancing Reading in Older Underperf. Students
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Years to 16 Years · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

NCT04016779
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Placebo, SPN-812
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
37
States / cities
Garden Grove, California • Los Alamitos, California • Newport Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 2Phase 3 Interventional

OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD

NCT02215538
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OROS methylphenidate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth

NCT01109849
View directory record Official record
Conditions
ADHD, Growth
Interventions
behavior therapy, Extended release (ER) methylphenidate product, monitoring, drug holiday, caloric supplement
Behavioral · Drug · Other + 1 more
Lead sponsor
Florida International University
Other
Eligibility
5 Years to 12 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2017 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Results available

Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

NCT00889915
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate transdermal system, Lisdexamfetamine dimesylate, Osmotic-release oral system methylphenidate (OROS MPH), Mixed amphetamine salts extended release
Drug
Lead sponsor
Duke University
Other
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

NCT01993108
View directory record Official record
Conditions
Healthy, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Naltrexone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study

NCT00764868
View directory record Official record
Conditions
ADHD
Interventions
Lisdexamfetamine Dimesylate (LDX)
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 6, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Treatment of Youth With ADHD and Anxiety

NCT00012584
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Anxiety, Separation, Social Phobia, Generalized Anxiety Disorder
Interventions
methylphenidate, fluvoxamine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
5
States / cities
Los Angeles, California • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2009 · Synced Oct 6, 2026, 9:33 AM EDT